Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Infectious complications after 2-chlorodeoxyadenosine therapy

E Van Den Neste1, A Delannoy, B Vandercam

  • 1Hematology Group of the Université Catholique de Louvain, Cliniques Universitaires St-Luc, Brussels, Beligum.

European Journal of Haematology
|April 1, 1996
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) in Belgium: a real world data analysis.

Acta clinica Belgica·2021
Same author

Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study.

BMC cancer·2021
Same author

Palmar fasciitis and polyarthritis, a rare paraneoplastic syndrome related to ovarian cancer.

Clinical and experimental dermatology·2017
Same author

Practical Epidemiology.

Acta clinica Belgica·2016
Same author

Breast prosthesis infection and pets: A case report and review of the literature.

International journal of surgery case reports·2016
Same author

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2015

Nucleoside analog therapy, including 2-chlorodeoxyadenosine (CdA), significantly increases infection risk in patients with hematological malignancies. Identifying high-risk patients is crucial for implementing targeted preventive measures against CdA-related infections.

Area of Science:

  • Oncology
  • Infectious Diseases
  • Hematology

Background:

  • Infections are frequent adverse events associated with nucleoside analog chemotherapy.
  • The incidence and risk factors for infections during 2-chlorodeoxyadenosine (CdA) therapy are not well-documented.

Purpose of the Study:

  • To compare the incidence of infectious episodes before and after initiating CdA therapy.
  • To identify patient-specific factors associated with an increased risk of infection post-CdA treatment.

Main Methods:

  • A retrospective study comparing infectious episodes in 95 hematological malignancy patients during the 6 months before and after CdA initiation.
  • Analysis of patient history, diagnosis, and laboratory counts to identify infection risk factors.

Related Experiment Videos

Main Results:

  • The incidence of infectious episodes nearly doubled after CdA therapy (0.87 vs. 0.47 episodes per patient).
  • Increased infection risk was linked to prior chemotherapy, pre-CdA infections, chronic lymphocytic leukemia, and non-Hodgkin's lymphoma diagnoses.
  • A shift in infection patterns was observed, with more herpes virus infections and fevers of unknown origin post-CdA.

Conclusions:

  • A significant increase in infection incidence occurs after CdA therapy.
  • Specific patient groups, including those with prior chemotherapy or certain hematological diagnoses, are at higher risk.
  • Targeted interventions are recommended for high-risk populations to mitigate CdA-related infectious complications.